Last checked at 10 Jun 2015 11:41
Venture Life Group plc
("Venture Life" or "the Group")
AGM Statement
Bracknell, UK - 10 June 2015: Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, held its Annual General Meeting earlier today.
Following the formal proceedings of the meeting, during which all resolutions were duly passed, Venture Life's non-executive Chair, Dr. Lynn Drummond, made the following statement:
"I am pleased to report that the Group's performance to date in 2015 has been encouraging and in line with expectations. The deals announced earlier in the year are progressing as expected and we remain positive about the outlook for the full year."
- Ends -
For further information please contact:
Venture Life Group PLC
Jerry Randall, Chief Executive Officer +44 (0) 1344 742870
James Hunter, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser and Broker) Freddy Crossley +44 (0) 20 7886 2500
Duncan Monteith Corporate Finance
Tom SalvesenCorporate Broking
Square1 Consulting
David Bick +44 (0) 20 7929 5599
Mark Longson
Notes to editors
About Venture Life
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.
Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
The Group's own branded products are currently sold or partnered in over 40 countries and currently include:
· food supplements to maintain brain function and memory;
· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and
· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.
The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.